Toggle Main Menu Toggle Search

Open Access padlockePrints

Upregulation of Anti-Angiogenic miR-106b-3p Correlates Negatively with IGF-1 and Vascular Health Parameters in a Model of Subclinical Cardiovascular Disease: Study with Metformin Therapy

Lookup NU author(s): Dr Sherin Bakhashab, Josie O'Neill, Rosie Barber, Dr Catherine ArdenORCiD, Dr Jolanta Weaver

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 by the authors.Well-controlled type 1 diabetes mellitus (T1DM) is regarded as a model of subclinical cardiovascular disease (CVD), characterized by inflammation and adverse vascular health. However, the underlying mechanisms are not fully understood. We investigated insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) levels, their correlation to miR-106b-3p expression in a subclinical CVD model, and the cardioprotective effect of metformin. A total of 20 controls and 29 well-controlled T1DM subjects were studied. Plasma IGF-1, IGFBP-3 levels, and miR-106b-3p expression in colony-forming unit-Hills were analyzed and compared with vascular markers. miR-106b-3p was upregulated in T1DM (p < 0.05) and negatively correlated with pro-angiogenic markers CD34+/100-lymphocytes (p < 0.05) and IGF-1 (p < 0.05). IGF-1 was downregulated in T1DM (p < 0.01), which was associated with increased inflammatory markers TNF-α, CRP, and IL-10 and reduced CD34+/100-lymphocytes. IGFBP-3 had no significant results. Metformin had no effect on IGF-1 but significantly reduced miR-106b-3p (p < 0.0001). An Ingenuity Pathway analysis predicted miR-106b-3p to inhibit PDGFA, PIK3CG, GDNF, and ADAMTS13, which activated CVD. Metformin was predicted to be cardioprotective by inhibiting miR-106b-3p. In conclusion: Subclinical CVD is characterized by a cardio-adverse profile of low IGF-1 and upregulated miR-106b-3p. We demonstrated that the cardioprotective effect of metformin may be via downregulation of upregulated miR-106b-3p and its effect on downstream targets.


Publication metadata

Author(s): Bakhashab S, O'Neill J, Barber R, Arden C, Weaver JU

Publication type: Article

Publication status: Published

Journal: Biomedicines

Year: 2024

Volume: 12

Issue: 1

Online publication date: 12/01/2024

Acceptance date: 09/01/2024

Date deposited: 05/02/2024

ISSN (electronic): 2227-9059

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

URL: https://doi.org/10.3390/biomedicines12010171

DOI: 10.3390/biomedicines12010171

Data Access Statement: All data are contained within the article and Supplementary Material.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Diabetes Research and Wellness Foundation
the Diabetes Research Fund at Queen Elizabeth Hospital, Gateshead, UK.

Share